Results 131 to 140 of about 4,214,171 (152)

Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector.

Journal of Clinical Oncology
161 Background: PSMA-targeted radionuclide therapy (PSMA-TRT) has been established with use of either monoclonal antibodies (mAb) or small molecule ligands (SML) as the targeting vectors for delivery of 177Lu to PSMA-expressing prostate cancer. mAb and SML differ in their molecular weight, pharmacokinetics, and biodistribution which is predicted to ...
Samuel Francis Ruder, Michael Philip Sun, Charlene Thomas, Ana M. Molina, Jones T. Nauseef, Joseph Osborne, Cora N. Sternberg, David M. Nanus, Neil Harrison Bander, Scott T. Tagawa   +9 more
openaire   +1 more source

Abstract 7582: Descriptive analysis of patients with mCRPC and liver metastases receiving alpha and beta PSMA targeted radionuclide therapy (PSMA-TRT)

Cancer Research
Abstract Introduction: Predictors of outcomes after PSMA-TRT are still being established. Liver metastases (mets) have been associated with poor response. Mutations in genes encoding DNA damage repair (DDR) and TP53 affect radiosensitivity.
Samuel Ruder, Michael Sun, Andres Ricaurte Fajardo, Jones Nauseef, Zachary Davidson, Joseph Thomas, Sandra Huicochea Castellanos, Ana Molina, Cora Sternberg, Amie Patel, Escarleth Fernandez, Sarah Yuan, Edward Fung, Vasilios Avlonitis, Elisabeth O'Dwyer, David Nanus, Joseph Osborne, Neil Bander, Scott Tagawa   +18 more
openaire   +1 more source

1822P PSMA-alpha targeted radionuclide therapy (TRT) with or without prior PSMA-beta TRT

Annals of Oncology, 2023
M. Sun, C. Thomas, J. Stangl-Kremser, A. Fajardo, J. Palmer, J. Thomas, S. Huicochea Castellanos, J. Osborne, J. Nauseef, A.M. Molina, C.N. Sternberg, D.M. Nanus, N.H. Bander, S.T. Tagawa   +13 more
openaire   +1 more source

Abstract 5276: [123I]CC1, a radiopharmaceutical for Targeted radionuclide therapy (TRT), exploits PARP binding and trapping to amplify DNA damage and cytotoxicity in human cancer cell lines

Cancer Research
Abstract We investigated whether the antitumor effects of [123I]CC1, a PARP-binding radiopharmaceutical emitting very short-range ionising Auger electrons with potential use in Targeted Radionuclide Therapy (TRT), are driven by PARP trapping. Trapping will prolong its residence time on DNA and triggers more DNA damage.
Luis Hernandez Cano, Nerea Delgado Mayenco, Hilleen Kramer, Elmar Diekstra, Francesca Amoroso, George Alachouzos, Wiktor Szymanski, Frank A. Kruyt, Bart Cornelissen   +8 more
openaire   +1 more source

1390P Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)

Annals of Oncology, 2022
M. Sun, C. Thomas, F. Orlando, M. Sigouros, J. Osborne, J. Nauseef, A.M. Molina, C. Sternberg, M. Bissassar, S. Singh, F. Khani, D.M. Nanus, K. Ballman, N. Bander, F. Demichelis, H. Beltran, S.T. Tagawa   +16 more
openaire   +1 more source

Quantificazione assoluta dell'attività per TRT (Targeted Radionuclide Therapy) con Lutezio 177.

2018
Nella terapia con radionuclidi, la necessità di quantificare l'attività negli organi di interesse è di fondamentale importanza: essa è la base per una corretta valutazione della dose, specialmente in vista dell'attuazione della direttiva Europea 2013/59/EURATOM. Nella prima parte del lavoro, si è testato e validato il Monte Carlo SIMIND, simulando
DI BIASO, SIMONA, Di Domenico G., Tonini E., Turra A.   +3 more
openaire   +1 more source

Feasibility of the Systemic Cure of Cancer With Targeted Radionuclide Therapy (TRT)

International Journal of Radiation Oncology*Biology*Physics, 2012
T.W. Speer, P. Bernhardt, B. Bednarz, P. Harari, J. Saker, B. Thomadsen   +5 more
openaire   +1 more source

MP29-10 PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED RADIONUCLIDE THERAPY (TRT)

Journal of Urology, 2023
Judith Stangl-Kremser, Michael Sun, Benedict Ho, Joseph Thomas, Jones Nauseef, Joseph Osborne, Ana Molina, Cora Sternberg, David Nanus, Neil Bander, Scott Tagawa   +10 more
openaire   +1 more source

The Broadening Scope of Oral Mucositis and Oral Ulcerative Mucosal Toxicities of Anticancer Therapies

Ca-A Cancer Journal for Clinicians, 2022
Stephen Sonis, Noam Yarom, Michal Kuten-Shorrer   +2 more
exaly  

Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment

Pharmaceutics, 2023
Zachary S Morris, Reinier Hernandez, Caroline P Kerr   +2 more
exaly